Beginning tomorrow, July 1, 2023, CYLTEZO® (adalimumab-adbm) will become the first HUMIRA® (adalimumab) biosimilar with interchangeable status to be commercially available in the United States. Boehringer Ingelheim has also announced that with CYLTEZO’s commercial launch, pharmacy-benefit manager Optum Rx (a subsidiary of UnitedHealth Group), which currently covers more than 66 million patients, will place CYLTEZO
Latest Post
More Posts
Celltrion Launches VEGZELMA in the United States
Sandoz denosumab BLA accepted by US FDA
Biocon Biologics Confirms Completion of Multi-Billion Dollar Acquisition of Viatris’ Global Biosimilars Business
China Approves World’s First Denosumab Biosimilar
PTAB Grants Petitioner Celltrion’s Motion To Submit Supplemental Information in Tocilizumab IPR
The Future of Patents for Patients: USPTO Temporarily Extends Cancer Immunotherapy Pilot Program (Patents for Patients) and Requests Public Input On Next Steps
Subscribe: Subscribe via RSS
Firm/Org